Osteomalacia

Definition

Osteomalacia is a metabolic bone disease characterized by defective mineralization of newly formed osteoid in mature bone. It represents the adult equivalent of rickets, which affects growing bones in children. The hallmark is accumulation of unmineralized or undermineralized osteoid matrix, resulting in soft, deformable bones with increased fracture risk.

Epidemiology

Normal bone mineralization requires adequate calcium, phosphate, and alkaline phosphatase. Vitamin D is essential for intestinal calcium absorption and renal phosphate reabsorption. In osteomalacia, deficiency of vitamin D or phosphate leads to:

Molecular cascade:

1. Reduced calcium and phosphate availability
2. Inadequate hydroxyapatite crystal formation in osteoid
3. Accumulation of unmineralized osteoid (increased osteoid volume)
4. Secondary hyperparathyroidism (compensatory response to hypocalcemia)
5. Further phosphate wasting (PTH-induced renal phosphate loss)
6. Progressive bone softening and deformity

Symptoms

Examination Findings

The topic repeatedly invokes proximal myopathy (waddling gait, difficulty rising from a chair, and one of the three cardinal features), but the muscle disorder itself deserves separate development because it is a favourite viva follow-up ("why is this patient weak?") and its features are what distinguish it from the many other myopathies an examiner might offer.

Mechanism

Two deficiencies act together on muscle:

• Vitamin D / calcitriol deficiency. Skeletal muscle expresses the vitamin D receptor; calcitriol influences myocyte calcium handling and the maintenance of fast-twitch type II fibres. Deficiency produces selective type II fibre atrophy on muscle histology.
• Hypophosphatemia. Phosphate is required for ATP generation and for the phosphocreatine energy shuttle; low serum phosphate impairs muscle contractility and energy supply, contributing directly to weakness and fatigue.

Clinical and Laboratory Features

Reversibility

Osteomalacic myopathy is reversible with correction of the underlying deficiency. Muscle power typically begins to improve within a few weeks and largely recovers over 3-6 months of vitamin D (and, where relevant, phosphate) replacement - often before radiographic healing of Looser zones. Persistent weakness after adequate replacement should prompt a search for a second, unrelated neuromuscular cause.

Biochemistry

Vitamin D Thresholds:

• Severe deficiency: less than 25 nmol/L (less than 10 ng/mL)
• Deficiency: 25-50 nmol/L (10-20 ng/mL)
• Insufficiency: 50-75 nmol/L (20-30 ng/mL)
• Optimal for bone health: 75-125 nmol/L (30-50 ng/mL)

Additional Investigations

• Urinary calcium: low (less than 2.5 mmol per 24 hours)
• Urinary phosphate: elevated in renal phosphate wasting
• FGF23 level: elevated in tumor-induced osteomalacia (oncogenic osteomalacia)
• Renal function: to assess for chronic kidney disease (impaired 1-alpha hydroxylation)
• Liver function: to assess for cholestatic disease (impaired vitamin D absorption)

The topic names the biopsy findings that define osteomalacia - increased osteoid volume, widened osteoid seams, prolonged mineralization lag time, and delayed tetracycline labelling - and the burosumab evidence card reports reversal of exactly these parameters. Because the transiliac biopsy remains the histological gold standard, it is worth understanding how the technique actually produces those numbers and which combination is diagnostic.

How Tetracycline Double-Labelling Works

Tetracyclines chelate calcium and fluoresce, so they deposit as a bright band wherever active mineralization is occurring at the time of dosing. Two short courses are given before the (undecalcified) transiliac biopsy, separated by a label-free interval (a common schedule is a short course, roughly a fortnight off, then a second short course, with biopsy a few days later):

• The distance between the two fluorescent labels, divided by the number of days between them, gives the mineral apposition rate (MAR) in micrometres per day (normal roughly 0.6 to 1.0).
• The mineralization lag time (MLT) is derived from osteoid seam thickness relative to the apposition rate - it is the time osteoid waits before it mineralizes (normal under roughly 20 to 25 days; osteomalacia greater than 100 days).
• In severe osteomalacia mineralization is so impaired that there may be only a single, diffuse ("smudgy") label or no uptake at all - itself a strong pointer to the diagnosis.

The Diagnostic Combination (Not Osteoid Alone)

Pathological Fractures

Arthroplasty Considerations

Expected Response to Treatment

Global Epidemiology

• Vitamin D deficiency is one of the most prevalent micronutrient deficiencies worldwide, but its consequences vary by latitude, skin pigmentation, diet, sun exposure and food-fortification policy.
• Nutritional osteomalacia remains common in South Asia, the Middle East and North Africa, driven by limited effective UVB exposure (concealing dress, high latitude in winter, air pollution) and low dietary calcium/vitamin D.
• In high-income countries, frank osteomalacia is now mostly seen in the institutionalized elderly, malabsorption (coeliac disease, IBD, post-bariatric surgery), chronic kidney/liver disease, and dark-skinned migrants at higher latitudes.

Side-by-Side Guideline Comparison

• Key controversy: the Endocrine Society favours a higher individual target (above 75 nmol/L) for at-risk patients, whereas the IOM and several national bodies regard about 50 nmol/L as adequate for the general population. For symptomatic/biopsy-proven osteomalacia all bodies agree on therapeutic replacement plus calcium.

Registry & Outcome Notes

• There is no dedicated osteomalacia registry; relevant arthroplasty registries (NJR, AJRR, AOANJRR, Swedish/Norwegian) track revision and periprosthetic fracture, where poor bone quality and metabolic bone disease are recognised contributors to early failure and periprosthetic fracture.

High- vs Limited-Resource Practice

• High-resource: routine 25-OH vitamin D, PTH, FGF23 assays; functional imaging (68Ga-DOTATATE PET/CT, whole-body MRI) for TIO; access to burosumab and calcitriol.
• Limited-resource: diagnosis often clinical/radiographic and biochemical (calcium, phosphate, ALP); calcium plus vitamin D remains the cost-effective cornerstone and the global consensus stresses combined calcium-vitamin D because dietary calcium deficiency alone can cause osteomalacia/rickets even with adequate vitamin D.

Oncogenic Osteomalacia

• Rare FGF23-secreting mesenchymal tumours require functional then anatomical imaging (68Ga-DOTATATE PET/CT, whole-body MRI, selective venous FGF23 sampling) for localisation. Surgical excision is curative; burosumab is the option for unresectable/unlocalised disease.